Works matching IS 00126667 AND DT 2025 AND VI 85 AND IP 4

Results: 11

Revumenib: First Approval: Revumenib: First Approval: Y. Y. Syed.

Published in:

Drugs, 2025, v. 85, n. 4, p. 577, doi. 10.1007/s40265-025-02161-5

By:

Syed, Yahiya Y.

Publication type:

Article

Olezarsen: First Approval: Olezarsen: First Approval: Y. Y. Syed.

Published in:

Drugs, 2025, v. 85, n. 4, p. 571, doi. 10.1007/s40265-025-02166-0

By:

Syed, Yahiya Y.

Publication type:

Article

Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies: Systematic Review of Post-marketing Safety Surveillance Studies of Anti-OA Drugs: G. Honvo et al.

Published in:

Drugs, 2025, v. 85, n. 4, p. 505, doi. 10.1007/s40265-025-02162-4

By:

Honvo, Germain;
Lengelé, Laetitia;
Alokail, Majed;
Al-Daghri, Nasser;
Reginster, Jean-Yves;
Bruyère, Olivier

Publication type:

Article

From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology: Model-Informed Dose Optimization in Oncology: B. C. Agema et al.

Published in:

Drugs, 2025, v. 85, n. 4, p. 487, doi. 10.1007/s40265-025-02152-6

By:

Agema, Bram C.;
Koch, Birgit C. P.;
Mathijssen, Ron H. J.;
Koolen, Stijn L. W.

Publication type:

Article

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes: Emerging Immunotherapies for Disease Modification of T1DM: T. P. Foster et al.

Published in:

Drugs, 2025, v. 85, n. 4, p. 457, doi. 10.1007/s40265-025-02150-8

By:

Foster, Timothy P.;
Bruggeman, Brittany S.;
Haller, Michael J.

Publication type:

Article

Update on the Treatment of Chronic Spontaneous Urticaria: Update on the Treatment of Chronic Spontaneous Urticaria: P. Kolkhir et al.

Published in:

Drugs, 2025, v. 85, n. 4, p. 475, doi. 10.1007/s40265-025-02170-4

By:

Kolkhir, Pavel;
Fok, Jie Shen;
Kocatürk, Emek;
Li, Philip H.;
Okas, Tiia-Linda;
Marcelino, Joao;
Metz, Martin

Publication type:

Article

Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON): Safety and Duration of IOP Control with Bimatoprost Implant: S. M. Silverstein et al.

Published in:

Drugs, 2025, v. 85, n. 4, p. 557, doi. 10.1007/s40265-025-02154-4

By:

Silverstein, Steven M.;
Oddone, Francesco;
Kolko, Miriam;
Brinkmann, Christian K.;
Christie, William C.;
Bicket, Amanda K.;
Gous, Petrus N. J.;
Luebke, Jan;
Maram, Jyotsna;
Nguyen, Ashley;
Craven, E. Randy;
Pu, Yongjia;
Jiao, Jenny;
Bejanian, Marina;
Robinson, Michael R.;
Bercovich, Gabriel;
Gentile, Carolina;
Lerner, Simon Fabian;
Lupinacci, Anahi;
Santos, Rodrigo

Publication type:

Article

Tasurgratinib Succinate: First Approval: Tasurgratinib Succinate: First Approval: Y. N. Lamb.

Published in:

Drugs, 2025, v. 85, n. 4, p. 585, doi. 10.1007/s40265-025-02153-5

By:

Lamb, Yvette N.

Publication type:

Article

Correction: Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan: Blocking the IL-5 Pathway in Eosinophilic Disorders: C. Lombardi et al.

Published in:

2025

By:

Lombardi, Carlo;
Comberiati, Pasquale;
Ridolo, Erminia;
Cottini, Marcello;
Yacoub, Mona Rita;
Casagrande, Silvia;
Riccò, Matteo;
Bottazzoli, Marco;
Berti, Alvise

Publication type:

Correction Notice

Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid: Glucocorticoid-Free Management of Lupus Nephritis?: Y. Tanaka.

Published in:

Drugs, 2025, v. 85, n. 4, p. 447, doi. 10.1007/s40265-025-02156-2

By:

Tanaka, Yoshiya

Publication type:

Article

Zenocutuzumab: First Approval: Zenocutuzumab: First Approval: H. A. Blair.

Published in:

Drugs, 2025, v. 85, n. 4, p. 591, doi. 10.1007/s40265-025-02155-3

By:

Blair, Hannah A.

Publication type:

Article